Stylianos A. Pyxaras1, MD; William Wijns2*, MD, PhD
1. Medizinische Klinik I, Landshut-Achdorf Krankenhaus, Landshut, Germany; 2. The Lambe Institute for Translational Medicine and Curam, National University of Ireland, Galway, and Saolta University Healthcare Group, Galway, Ireland
“We tend to overestimate the effect of a technology in the short run and underestimate the effect in the long run.”
Roy Amara’s law
Bioresorbable coronary scaffolds (BRS) have been developed to achieve stenosis dilatation and stenting while uncaging the coronary vessels from permanent metallic structures. Uncaging the vessels in order to allow restoration of physiology has become a significant unmet need, especially when dealing with complex multivessel or diffuse disease that requires long vessel segments to be stented. The timing, however, for introducing the disruptive bioresorbable technology could not have been worse. First-generation BRS were ...